Table 1.
Summary data on candidate interacting precipitants and semi-Bayes shrunk rate ratios for unintentional traumatic injury, by antidepressant object drug
| Object drug | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Amitriptyline | Amoxapine | Bupropion | Citalopram | Clomipramine | Desipramine | Desvenlafaxine | Doxepin | Duloxetine | |
| Unadjusted analyses | |||||||||
| Candidate interacting precipitants examined, count | 495 | 21 | 483 | 549 | 121 | 175 | 303 | 341 | 485 |
| DDI signals, count (%) | 33 (6.7) | 0 (0.0) | 37 (7.7) | 50 (9.1) | 1 (0.8) | 0 (0.0) | 9 (3.0) | 13 (3.8) | 30 (6.2) |
| Increased rate* | 11 (2.2) | 0 (0.0) | 13 (2.7) | 19 (3.5) | 0 (0.0) | 0 (0.0) | 4 (1.3) | 4 (1.2) | 13 (2.7) |
| Decreased rate** | 22 (4.4) | 0 (0.0) | 24 (5.0) | 31 (5.6) | 1 (0.8) | 0 (0.0) | 5 (1.7) | 9 (2.6) | 17 (3.5) |
| RR range, min to max | 0.40 – 1.92 | 0.69 – 1.27 | 0.55 – 2.15 | 0.41 – 2.52 | 0.45 – 1.85 | 0.63 – 2.08 | 0.50 – 2.09 | 0.54 – 1.89 | 0.58 – 2.60 |
| Confounder-adjusted analyses | |||||||||
| Candidate interacting precipitants examined, count | 495 | 21 | 483 | 549 | 121 | 174 | 303 | 341 | 484 |
| DDI signals, count (%) | 40 (8.1) | 0 (0.0) | 38 (7.9) | 55 (10.0) | 1 (0.8) | 2 (1.1) | 10 (3.3) | 11 (3.2) | 32 (6.6) |
| Increased rate* | 16 (3.2) | 0 (0.0) | 16 (3.3) | 27 (4.9) | 0 (0.0) | 2 (1.1) | 5 (1.7) | 5 (1.5) | 16 (3.3) |
| Decreased rate** | 24 (4.8) | 0 (0.0) | 22 (4.6) | 28 (5.1) | 1 (0.8) | 0 (0.0) | 5 (1.7) | 6 (1.8) | 16 (3.3) |
| RR range, min to max | 0.39 – 1.94 | 0.60 – 1.26 | 0.55 – 2.19 | 0.42 – 2.45 | 0.52 – 1.98 | 0.59 – 2.10 | 0.50 – 2.08 | 0.50 – 2.05 | 0.55 – 2.62 |
| Escitalopram | Fluoxetine | Fluvoxamine | Imipramine | Levomilna. | Maprotiline | Mirtazapine | Nefazodone | Nortriptyline | |
| Unadjusted analyses | |||||||||
| Candidate interacting precipitants examined, count | 560 | 546 | 181 | 296 | 11 | 13 | 449 | 206 | 384 |
| DDI signals, count (%) | 39 (7.0) | 39 (7.1) | 6 (3.3) | 3 (1.0) | 0 (0.0) | 0 (0.0) | 30 (6.7) | 4 (1.9) | 17 (4.4) |
| Increased rate* | 18 (3.2) | 16 (2.9) | 5 (2.8) | 2 (0.7) | 0 (0.0) | 0 (0.0) | 25 (5.6) | 3 (1.5) | 9 (2.3) |
| Decreased rate** | 21 (3.8) | 23 (4.2) | 1 (0.6) | 1 (0.3) | 0 (0.0) | 0 (0.0) | 5 (1.1) | 1 (0.5) | 8 (2.1) |
| RR range, min to max | 0.43 – 1.95 | 0.59 – 2.18 | 0.43 – 2.24 | 0.55 – 2.10 | 1.23 – 2.31 | 0.91 – 2.06 | 0.55 – 2.22 | 0.59 – 3.05 | 0.57 – 2.44 |
| Confounder-adjusted analyses | |||||||||
| Candidate interacting precipitants examined, count | 560 | 545 | 181 | 294 | 11 | 13 | 449 | 206 | 383 |
| DDI signals, count (%) | 39 (7.0) | 41 (7.5) | 7 (3.9) | 5 (1.7) | 0 (0.0) | 0 (0.0) | 34 (7.6) | 5 (2.4) | 16 (4.2) |
| Increased rate* | 20 (3.6) | 20 (3.7) | 5 (2.8) | 3 (1.0) | 0 (0.0) | 0 (0.0) | 24 (5.3) | 5 (2.4) | 10 (2.6) |
| Decreased rate** | 19 (3.4) | 21 (3.9) | 2 (1.1) | 2 (0.7) | 0 (0.0) | 0 (0.0) | 10 (2.2) | 0 (0.0) | 6 (1.6) |
| RR range, min to max | 0.41 – 2.06 | 0.48 – 2.28 | 0.45 – 2.26 | 0.48 – 2.15 | 1.36 – 2.54 | 0.91 – 2.06 | 0.52 – 2.38 | 0.61 – 3.06 | 0.53 – 2.96 |
| Paroxetine | Protriptyline | Sertraline | Trazodone | Trimipramine | Venlafaxine | Vilazodone | Vortioxetine | ||
| Unadjusted analyses | |||||||||
| Candidate interacting precipitants examined, count | 529 | 36 | 567 | 490 | 2 | 510 | 164 | 44 | |
| DDI signals, count (%) | 35 (6.6) | 0 (0.0) | 62 (10.9) | 30 (6.1) | 0 (0.0) | 45 (8.8) | 0 (0.0) | 0 (0.0) | |
| Increased rate* | 13 (2.5) | 0 (0.0) | 23 (4.1) | 13 (2.7) | 0 (0.0) | 18 (3.5) | 0 (0.0) | 0 (0.0) | |
| Decreased rate** | 22 (4.2) | 0 (0.0) | 39 (6.9) | 17 (3.5) | 0 (0.0) | 27 (5.3) | 0 (0.0) | 0 (0.0) | |
| RR range, min to max | 0.50 – 2.01 | 0.78 – 1.87 | 0.48 – 2.44 | 0.40 – 1.99 | 0.81 – 0.86 | 0.51 – 1.79 | 0.57 – 2.05 | 0.73 – 1.72 | |
| Confounder-adjusted analyses | |||||||||
| Candidate interacting precipitants examined, count | 528 | 36 | 567 | 490 | 2 | 510 | 164 | 43 | |
| DDI signals, count (%) | 35 (6.6) | 0 (0.0) | 60 (10.6) | 30 (6.1) | 0 (0.0) | 46 (9.0) | 0 (0.0) | 0 (0.0) | |
| Increased rate* | 17 (3.2) | 0 (0.0) | 28 (4.9) | 16 (3.3) | 0 (0.0) | 21 (4.1) | 0 (0.0) | 0 (0.0) | |
| Decreased rate** | 18 (3.4) | 0 (0.0) | 32 (5.6) | 14 (2.9) | 0 (0.0) | 25 (4.9) | 0 (0.0) | 0 (0.0) | |
| RR range, min to max | 0.48 – 1.98 | 0.80 – 1.88 | 0.47 – 2.44 | 0.42 – 2.02 | 1.20 – 1.26 | 0.46 – 1.81 | 0.57 – 2.02 | 0.67 – 1.63 | |
DDI = drug-drug interaction; levomilna. = levomilnacipran; max = maximum; min = minimum; RR = rate ratio
*
lower bound of the 95% confidence interval for the RR of interest excluded the null value
**
upper bound of the 95% confidence interval for the RR of interest excluded the null value